Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00629200 · ClinicalTrials.gov registry record · Phase 1
Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT00629200: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00629200 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00629200, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
Primary Objective: -To determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of SSG in combination with IFN alpha2b in patients with advanced malignancies. Secondary Objectives: * To correlate the AUC of SSG with clinical toxicity and efficacy. * To quantify the effect of SSG on IFN alpha2b induced gene modulation and signal transduction pathways. * To characterize the effects of SSG on PTPases SHP-1 and SHP-2. * To assess the safety, efficacy, and PK of SSG in combination with IFN alpha2b.
Interventions
- DRUG Sodium Stibogluconate
- DRUG Interferon Alpha-2b
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2006-09-13 |
| Est. Completion | 2010-02-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00629200
The ClinicalTrials.gov registry entry for NCT00629200 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sodium Stibogluconate is the first listed.
NCT00629200 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00629200 about?
NCT00629200 is a clinical study titled "Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies". Primary Objective: -To determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of SSG in combination with IFN alpha2b in patients with advanced malignancies. Secondary Objectives: * To correlate the AUC of SSG with clinical toxicity and efficacy. * To quantify the effect of SS...
What is the current status of trial NCT00629200?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2006-09-13. Estimated completion is 2010-02-10.
What interventions are being tested in trial NCT00629200?
The interventions under investigation include: Sodium Stibogluconate (DRUG), Interferon Alpha-2b (DRUG).
Who is sponsoring clinical trial NCT00629200?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.